Form 4: FRACTYL HEALTH, INC.: Executive Acquires Stock Options
SEC Form 4
Jay David Caplan, President and Chief Product Officer of FRACTYL HEALTH, INC., reports acquisition of stock options.
Summary
- Jay David Caplan, President and Chief Product Officer of FRACTYL HEALTH, INC. acquired stock options on February 27, 2025.
- Caplan acquired options to purchase 179,700 shares at an exercise price of $1.46, vesting in equal installments over four years from the grant date, and expiring on February 26, 2035.
- Additionally, Caplan acquired options to purchase 104,400 shares at an exercise price of $15, vesting in installments over three years, expiring on January 31, 2034.
- The vesting of the 104,400 shares is contingent upon the satisfaction of certain performance criteria, which were partially met, resulting in the vesting of 25% of the shares on December 31, 2024, with the remaining 75% vesting in substantially equal installments on the first three anniversaries thereof.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning management with shareholder interests. The vesting schedule and performance criteria suggest a focus on long-term value creation.
Positives
- The acquisition of stock options by a key executive aligns their interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The vesting of the options is tied to continued employment and, in the case of the 104,400 shares, the achievement of performance criteria.
Industry Context
Stock option grants are a common form of executive compensation in the health technology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the technology and healthcare sectors.
- Companies like Teladoc Health and Livongo (prior to its acquisition by Teladoc) have used similar stock option plans to incentivize their executives.
- The vesting schedules and performance criteria are generally in line with industry standards, designed to reward long-term value creation.
Stakeholder Impact
- Shareholders: The stock option grants align executive interests with shareholder value.
- Employees: The grants may motivate employees through the example set by executive compensation.
- Executive: The grants provide an incentive for the executive to drive company performance.
Key Dates
| Date | Description |
|---|---|
| 02/01/2024 | Reporting Person was granted, subject to the satisfaction of certain performance criteria, an option to purchase 174,000 shares of common stock to vest in the form of shares of the Issuer's common stock in four substantially equal installments on December 31, 2024 and each of the first three anniversaries thereof. |
| 12/31/2024 | 25% of 104,400 shares vested. |
| 02/27/2025 | Date of transaction: acquisition of stock options. |
| 03/03/2025 | Date of filing. |
| 01/31/2034 | Expiration date for 104,400 stock options. |
| 02/26/2035 | Expiration date for 179,700 stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.